humira_abbott_

AbbVie files lawsuit against Amgen over Humira copy

pharmafile | August 8, 2016 | News story | Research and Development, Sales and Marketing |  AbbVie, Amgen, FDA, Humira, rheumatoid arthritis 

Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis drug.

The company has asserted that Amgen’s proposed ABP 501 biosimilar would violate at least 10 of its patents and up to as many as 51 other patents, and is seeking a court order to prevent its sale.

In July, the US Food and Drug Administration (FDA) voiced its unanimous recommendation of the biosimilar after calling it ‘highly similar’ to the original Humira.

Advertisement

The active ingredient of ABP 501 is an anti-tumour necrosis factor-alpha (TNF-α) monoclonal antibody which has a similar amino acid sequence as Humira and can be used to treat a ranges of afflictions including rheumatoid and psioriatic arthritis, spondylitis, moderate to severe psoriasis and Crohn’s disease.

Matt Fellows

Related Content

FDA grants De Novo authorisation to light-filtering device for migraine

The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved …

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

The Gateway to Local Adoption Series

Latest content